EA033314B1 - АНТИБАКТЕРИАЛЬНЫЕ АГЕНТЫ, СОДЕРЖАЩИЕ ПИРАЗИНО[2,3-b][1,4]ОКСАЗИН-3-ОН ИЛИ РОДСТВЕННУЮ КОЛЬЦЕВУЮ СИСТЕМУ - Google Patents

АНТИБАКТЕРИАЛЬНЫЕ АГЕНТЫ, СОДЕРЖАЩИЕ ПИРАЗИНО[2,3-b][1,4]ОКСАЗИН-3-ОН ИЛИ РОДСТВЕННУЮ КОЛЬЦЕВУЮ СИСТЕМУ

Info

Publication number
EA033314B1
EA033314B1 EA201890412A EA201890412A EA033314B1 EA 033314 B1 EA033314 B1 EA 033314B1 EA 201890412 A EA201890412 A EA 201890412A EA 201890412 A EA201890412 A EA 201890412A EA 033314 B1 EA033314 B1 EA 033314B1
Authority
EA
Eurasian Patent Office
Prior art keywords
pyrazino
oxazin
antibacterials
ring system
related ring
Prior art date
Application number
EA201890412A
Other languages
English (en)
Russian (ru)
Other versions
EA201890412A1 (ru
Inventor
Хайфэн Цуй
Алан Хеннеси
Ци Цзинь
Тимоти Джеймс Майлс
Стивен Фредерик Мосс
Нейл Дэвид Пирсон
Original Assignee
Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед filed Critical Глаксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед
Publication of EA201890412A1 publication Critical patent/EA201890412A1/ru
Publication of EA033314B1 publication Critical patent/EA033314B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicinal Preparation (AREA)
EA201890412A 2015-08-16 2016-08-15 АНТИБАКТЕРИАЛЬНЫЕ АГЕНТЫ, СОДЕРЖАЩИЕ ПИРАЗИНО[2,3-b][1,4]ОКСАЗИН-3-ОН ИЛИ РОДСТВЕННУЮ КОЛЬЦЕВУЮ СИСТЕМУ EA033314B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562205732P 2015-08-16 2015-08-16
US201662308928P 2016-03-16 2016-03-16
PCT/IB2016/054890 WO2017029602A2 (en) 2015-08-16 2016-08-15 Compounds for use in antibacterial applications

Publications (2)

Publication Number Publication Date
EA201890412A1 EA201890412A1 (ru) 2018-08-31
EA033314B1 true EA033314B1 (ru) 2019-09-30

Family

ID=57218948

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201890412A EA033314B1 (ru) 2015-08-16 2016-08-15 АНТИБАКТЕРИАЛЬНЫЕ АГЕНТЫ, СОДЕРЖАЩИЕ ПИРАЗИНО[2,3-b][1,4]ОКСАЗИН-3-ОН ИЛИ РОДСТВЕННУЮ КОЛЬЦЕВУЮ СИСТЕМУ

Country Status (22)

Country Link
US (2) US10364254B2 (enExample)
EP (1) EP3334739A2 (enExample)
JP (1) JP6757402B2 (enExample)
KR (1) KR20180038046A (enExample)
CN (1) CN108137616B (enExample)
AU (2) AU2016307969C1 (enExample)
CA (1) CA2995715A1 (enExample)
CL (1) CL2018000403A1 (enExample)
CO (1) CO2018002204A2 (enExample)
CR (1) CR20180111A (enExample)
DO (1) DOP2018000049A (enExample)
EA (1) EA033314B1 (enExample)
HK (1) HK1248680A1 (enExample)
IL (1) IL257265B (enExample)
MA (1) MA42621A (enExample)
MX (1) MX2018002033A (enExample)
PE (1) PE20181143A1 (enExample)
PH (1) PH12018500358A1 (enExample)
TW (1) TW201722965A (enExample)
UY (1) UY36851A (enExample)
WO (1) WO2017029602A2 (enExample)
ZA (1) ZA201800722B (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UY36851A (es) * 2015-08-16 2017-03-31 Glaxosmithkline Ip Dev Ltd Compuestos para uso en aplicaciones antibacterianas
WO2019180634A1 (en) 2018-03-23 2019-09-26 Glaxosmithkline Intellectual Property Development Limited Synthesis of oxazinone-containing bicyclic aromatic and heteroaromatic aldehydes
WO2021009212A1 (en) 2019-07-16 2021-01-21 Idorsia Pharmaceuticals Ltd Antibacterial quinolone derivatives
CN111269247B (zh) * 2020-03-04 2020-11-24 河南科技大学第一附属医院 具有抑制大肠杆菌作用的噻嗪酮药物分子的制备方法
JP2025510646A (ja) 2022-03-14 2025-04-15 スラップ ファーマシューティカルズ エルエルシー 多環式化合物
WO2025132870A1 (en) 2023-12-21 2025-06-26 Glaxosmithkline Intellectual Property (No.4) Limited Chemical compounds and uses thereof

Citations (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4632671B1 (enExample) * 1969-10-13 1971-09-23 Eisai Co Ltd
WO2004002490A2 (en) * 2002-06-26 2004-01-08 Glaxo Group Limited Piperidine compounds as antibacterials
WO2004002992A1 (en) * 2002-06-26 2004-01-08 Glaxo Group Limited Compounds
WO2004087145A2 (en) * 2003-03-27 2004-10-14 Glaxo Group Limited Antibacterial agents
WO2006081264A1 (en) * 2005-01-25 2006-08-03 Glaxo Group Limited Antibacterial agents
WO2007093963A1 (en) * 2006-02-15 2007-08-23 Actelion Pharmaceuticals Ltd Ethanol or 1,2-ethanediol cyclohexyl antibiotic derivatives
WO2008078305A2 (en) * 2006-12-22 2008-07-03 Actelion Pharmaceuticals Ltd 4-(1-amino-ethyl)-cyclohexylamine derivatives
WO2008128961A1 (en) * 2007-04-20 2008-10-30 Glaxo Group Limited Compounds
US20090131444A1 (en) * 2005-05-24 2009-05-21 Astrazeneca Ab Aminopiperidine Quinolines and Their Azaisosteric Analogues with Antibacterial Activity
US20090270374A1 (en) * 2006-07-20 2009-10-29 Llius Ballell Derivatives and analogs of n-ethylquinolones and n-ethylazaquinolones
WO2010046388A1 (en) * 2008-10-23 2010-04-29 Glaxo Group Limited Substituted (aza) -1-methyl-1h-quinolin-2-ones as antibacterials
WO2010055348A1 (en) * 2008-11-14 2010-05-20 Astrazeneca Ab [4- (1-amino-ethyl) -cyclohexyl] -methyl-amines as antibacterials
WO2011148962A1 (ja) * 2010-05-25 2011-12-01 大正製薬株式会社 新規な複素環化合物又はその塩
US20140243302A1 (en) * 2011-06-27 2014-08-28 Merck Sharp & Dohme Corporation Bridged bicyclic compounds for the treatment of bacterial infections

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
GB2064336B (en) 1979-12-06 1984-03-14 Glaxo Group Ltd Device for dispensing medicaments
DE3274065D1 (de) 1981-07-08 1986-12-11 Draco Ab Powder inhalator
ES286422Y (es) 1982-10-08 1986-09-16 Glaxo Group Limited Dispositivo para administrar medicamentos a pacientes
GB2169265B (en) 1982-10-08 1987-08-12 Glaxo Group Ltd Pack for medicament
US4778054A (en) 1982-10-08 1988-10-18 Glaxo Group Limited Pack for administering medicaments to patients
AT396872B (de) 1985-07-30 1993-12-27 Glaxo Group Ltd Gerät zur verabreichung von medikamenten in pulverform
JPH0733379B2 (ja) * 1986-06-27 1995-04-12 エーザイ株式会社 光学活性α−トコフエロ−ルの製造方法
SK280967B6 (sk) 1990-03-02 2000-10-09 Glaxo Group Limited Inhalačný prístroj
US6536427B2 (en) 1990-03-02 2003-03-25 Glaxo Group Limited Inhalation device
GB9004781D0 (en) 1990-03-02 1990-04-25 Glaxo Group Ltd Device
IL115849A0 (en) 1994-11-03 1996-01-31 Merz & Co Gmbh & Co Tangential filtration preparation of liposomal drugs and liposome product thereof
GB9700226D0 (en) 1997-01-08 1997-02-26 Glaxo Group Ltd Inhalation device
US5827533A (en) 1997-02-06 1998-10-27 Duke University Liposomes containing active agents aggregated with lipid surfactants
FR2798656B1 (fr) 1999-09-17 2004-12-17 Aventis Pharma Sa Derives de la quinolyl propyl piperidine, leur preparation et les compositions qui les contiennent
DE60025048D1 (de) 2000-07-21 2006-01-26 Ljudmila Petrovna Maljuk Teller für stehempfänge
DE60125373T2 (de) 2000-07-26 2007-10-18 Smithkline Beecham P.L.C., Brentford Aminopiperidin chinoline und ihre azaisosteren analoga mit antibakterieller wirkung
FR2816618B1 (fr) 2000-11-15 2002-12-27 Aventis Pharma Sa Derives heterocyclylalcoyl piperidine, leur preparation et les compositions qui les contiennent
GB0031088D0 (en) 2000-12-20 2001-01-31 Smithkline Beecham Plc Medicaments
AU2002219175A1 (en) 2000-12-21 2002-07-01 Ciba Speciality Chemicals Holding Inc. Crystalline forms of cerivastatin sodium
GB0101577D0 (en) 2001-01-22 2001-03-07 Smithkline Beecham Plc Compounds
GB0112834D0 (en) * 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
GB0112836D0 (en) 2001-05-25 2001-07-18 Smithkline Beecham Plc Medicaments
GB0118238D0 (en) 2001-07-26 2001-09-19 Smithkline Beecham Plc Medicaments
GB0201677D0 (en) 2002-01-25 2002-03-13 Glaxo Group Ltd Medicament dispenser
WO2003064421A1 (en) 2002-01-29 2003-08-07 Glaxo Group Limited Aminopiperidine derivatives
AU2003239302A1 (en) 2002-01-29 2003-09-02 Glaxo Group Limited Aminopiperidine compounds, process for their preparation, and pharmaceutical compositions containing them
US20060014786A1 (en) * 2002-05-17 2006-01-19 Rajeev Raut Opthalmic pharmaceutical compositions and methods for treating ocular inflammation
AU2003279690A1 (en) 2002-06-27 2004-01-19 F. Hoffmann-La Roche Ag Synthesis of purine derivatives
GB0217294D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicaments
FR2844268B1 (fr) 2002-09-11 2004-10-22 Aventis Pharma Sa Derives de la quinolyl propyl piperidine, leurs procedes et intermediaires de preparation et les compositions qui les contiennent
FR2844270B1 (fr) 2002-09-11 2006-05-19 Aventis Pharma Sa Derives de la quinolyl propyl piperidine, leur procede et intermediaires de preparation et les compositions qui les contiennent
WO2004035569A2 (de) 2002-10-10 2004-04-29 Morphochem Aktiengesellschaft für kombinatorische Chemie Neue verbindungen mit antibakterieller aktivität
JP4704755B2 (ja) 2002-11-05 2011-06-22 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 抗菌剤
JP4654035B2 (ja) 2002-11-05 2011-03-16 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 抗菌剤
AR042486A1 (es) 2002-12-18 2005-06-22 Glaxo Group Ltd Compuesto de quinolina y naftiridina halosustituido en la posicion 3, procedimiento para preparar el compuesto, composicion farmaceutica que lo comprende y su uso para preparar dicha composicion .
FR2852954B1 (fr) 2003-03-28 2006-07-14 Aventis Pharma Sa Derives de quinoleines-4-substituees, leurs procede et intermediaires de preparation et les compositions pharmaceutiques qui les contiennent
DE10316081A1 (de) 2003-04-08 2004-10-21 Morphochem AG Aktiengesellschaft für kombinatorische Chemie Neue Verbindungen mit antibakterieller Aktivität
FR2858619B1 (fr) 2003-08-08 2006-12-22 Aventis Pharma Sa Derives de quinoleines-4-substituees, leurs procede et intermediaires de preparation et les compositions pharmaceutiques qui les contiennent
US9214590B2 (en) 2003-12-19 2015-12-15 The University Of North Carolina At Chapel Hill High fidelity nano-structures and arrays for photovoltaics and methods of making the same
KR101281775B1 (ko) 2003-12-19 2013-07-15 더 유니버시티 오브 노쓰 캐롤라이나 엣 채플 힐 소프트 또는 임프린트 리소그래피를 이용하여 분리된마이크로- 및 나노- 구조를 제작하는 방법
WO2007021762A2 (en) 2005-08-09 2007-02-22 The University Of North Carolina At Chapel Hill Methods and materials for fabricating microfluidic devices
FR2867472B1 (fr) 2004-03-12 2008-07-18 Aventis Pharma Sa Derives de quinoleines-4-substituees, leurs procede et intermediaires de preparation et les compositions pharmaceutiques qui les contiennent
US7691850B2 (en) 2004-06-15 2010-04-06 Glaxo Group Limited Antibacterial agents
FR2872164B1 (fr) 2004-06-29 2006-11-17 Aventis Pharma Sa Derives de quinoleines-4-substituees, leur procede et intermediaires de preparation et les compositions pharmaceutiques qui les contiennent
EP1773831A1 (en) 2004-07-08 2007-04-18 Glaxo Group Limited Antibacterial agents
WO2006010040A2 (en) 2004-07-09 2006-01-26 Glaxo Group Limited Antibacterial agents
EP1773343A4 (en) 2004-07-13 2009-05-13 Glaxo Group Ltd ANTIBACTERIAL AGENTS
JP2008507543A (ja) 2004-07-22 2008-03-13 グラクソ　グループ　リミテッド 抗細菌剤
ATE484509T1 (de) 2004-08-02 2010-10-15 Glaxo Group Ltd Antibakterielle mittel
US20070161627A1 (en) 2004-08-09 2007-07-12 Miller William H Antibacterial agents
DE102004041163A1 (de) 2004-08-25 2006-03-02 Morphochem Aktiengesellschaft für kombinatorische Chemie Neue Verbindungen mit antibakterieller Aktivität
JP4887297B2 (ja) 2004-09-24 2012-02-29 アクテリオン ファーマシューティカルズ リミテッド 新規二環式抗生物質
ATE466857T1 (de) 2004-10-05 2010-05-15 Actelion Pharmaceuticals Ltd Neue piperidin-antibiotika
JP5314244B2 (ja) 2004-10-27 2013-10-16 富山化学工業株式会社 新規な含窒素複素環化合物およびその塩
MY150958A (en) 2005-06-16 2014-03-31 Astrazeneca Ab Compounds for the treatment of multi-drug resistant bacterial infections
WO2006137485A1 (ja) 2005-06-24 2006-12-28 Toyama Chemical Co., Ltd. 新規な含窒素複素環化合物およびその塩
GB0515584D0 (en) 2005-07-28 2005-09-07 Glaxo Group Ltd Medicament dispenser
AR058289A1 (es) 2005-12-12 2008-01-30 Glaxo Group Ltd Colector para ser usado en dispensador de medicamento
DOP2006000268A (es) 2005-12-22 2007-07-31 Pfizer Prod Inc Agentes antibacterianos
US8944804B2 (en) 2006-01-04 2015-02-03 Liquidia Technologies, Inc. Nanostructured surfaces for biomedical/biomaterial applications and processes thereof
KR101409261B1 (ko) 2006-05-26 2014-06-18 다이쇼 세이야꾸 가부시끼가이샤 신규의 복소환 화합물 또는 그 염 및 그 중간체
WO2008013952A2 (en) 2006-07-27 2008-01-31 The University Of North Carolina At Chapel Hill Nanoparticle fabrication methods, systems, and materials for fabricating artificial red blood cells
US8128393B2 (en) 2006-12-04 2012-03-06 Liquidia Technologies, Inc. Methods and materials for fabricating laminate nanomolds and nanoparticles therefrom
WO2009024342A2 (en) * 2007-08-23 2009-02-26 Syngenta Participations Ag Novel microbiocides
CN101896337B (zh) 2007-10-12 2013-10-30 流体科技公司 用于生产颗粒和图案化膜的系统和方法
JP5620636B2 (ja) 2007-11-26 2014-11-05 富山化学工業株式会社 新規な複素環化合物またはその塩を含有する抗菌剤
MY158520A (en) * 2008-10-07 2016-10-14 Actelion Pharmaceuticals Ltd Tricyclic oxazolidinone antibiotic compounds
KR101690643B1 (ko) 2008-12-05 2016-12-28 리퀴디아 테크놀로지스 인코포레이티드 패턴 재료 제조 방법
CN102232078B (zh) * 2008-12-12 2014-07-16 埃科特莱茵药品有限公司 5-氨基-2-(1-羟基-乙基)-四氢吡喃衍生物
WO2011008737A2 (en) 2009-07-13 2011-01-20 The University Of North Carolina At Chapel Hill Engineered aerosol particles, and associated methods
CA2854266A1 (en) * 2011-11-30 2013-06-06 Actelion Pharmaceuticals Ltd 3,7-disubstituted octahydro-2h-pyrido[4,3-e][1,3]oxazin-2-one antibiotics
MX362338B (es) 2013-04-16 2019-01-11 Idorsia Pharmaceuticals Ltd Derivados biaromaticos antibacterianos.
UY36851A (es) * 2015-08-16 2017-03-31 Glaxosmithkline Ip Dev Ltd Compuestos para uso en aplicaciones antibacterianas

Patent Citations (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS4632671B1 (enExample) * 1969-10-13 1971-09-23 Eisai Co Ltd
WO2004002490A2 (en) * 2002-06-26 2004-01-08 Glaxo Group Limited Piperidine compounds as antibacterials
WO2004002992A1 (en) * 2002-06-26 2004-01-08 Glaxo Group Limited Compounds
WO2004087145A2 (en) * 2003-03-27 2004-10-14 Glaxo Group Limited Antibacterial agents
WO2006081264A1 (en) * 2005-01-25 2006-08-03 Glaxo Group Limited Antibacterial agents
US20090131444A1 (en) * 2005-05-24 2009-05-21 Astrazeneca Ab Aminopiperidine Quinolines and Their Azaisosteric Analogues with Antibacterial Activity
WO2007093963A1 (en) * 2006-02-15 2007-08-23 Actelion Pharmaceuticals Ltd Ethanol or 1,2-ethanediol cyclohexyl antibiotic derivatives
US20090270374A1 (en) * 2006-07-20 2009-10-29 Llius Ballell Derivatives and analogs of n-ethylquinolones and n-ethylazaquinolones
WO2008078305A2 (en) * 2006-12-22 2008-07-03 Actelion Pharmaceuticals Ltd 4-(1-amino-ethyl)-cyclohexylamine derivatives
US20100029623A1 (en) * 2006-12-22 2010-02-04 Actelion Pharmaceuticals Ltd. 4-(1-amino-ethyl)-cyclohexylamine derivatives
WO2008128961A1 (en) * 2007-04-20 2008-10-30 Glaxo Group Limited Compounds
WO2010046388A1 (en) * 2008-10-23 2010-04-29 Glaxo Group Limited Substituted (aza) -1-methyl-1h-quinolin-2-ones as antibacterials
WO2010055348A1 (en) * 2008-11-14 2010-05-20 Astrazeneca Ab [4- (1-amino-ethyl) -cyclohexyl] -methyl-amines as antibacterials
WO2011148962A1 (ja) * 2010-05-25 2011-12-01 大正製薬株式会社 新規な複素環化合物又はその塩
US20140243302A1 (en) * 2011-06-27 2014-08-28 Merck Sharp & Dohme Corporation Bridged bicyclic compounds for the treatment of bacterial infections

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
RECK FOLKERT; EHMANN DAVID E.; DOUGHERTY THOMAS J.; NEWMAN JOSEPH V.; HOPKINS SUSSIE; STONE GREGORY; AGRAWAL NIKUNJ; CIACCIO PAUL;: "Optimization of physicochemical properties and safety profile of novel bacterial topoisomerase type II inhibitors (NBTIs) with activity againstPseudomonas aeruginosa", BIOORGANIC & MEDICINAL CHEMISTRY : A TETRAHEDRON PUBLICATION FOR THE RAPID DISSEMINATION OF FULL ORIGINAL RESEARCH PAPERS AND CRITICAL REVIEWS ON BIOMOLECULAR CHEMISTRY, MEDICINAL CHEMISTRY AND RELATED DISCIPLINES, ELSEVIER, NL, vol. 22, no. 19, 4 August 2014 (2014-08-04), NL, pages 5392 - 5409, XP029061970, ISSN: 0968-0896, DOI: 10.1016/j.bmc.2014.07.040 *

Also Published As

Publication number Publication date
CO2018002204A2 (es) 2018-06-20
MX2018002033A (es) 2018-06-15
US20190270755A1 (en) 2019-09-05
DOP2018000049A (es) 2018-03-30
US10683307B2 (en) 2020-06-16
CN108137616B (zh) 2020-06-26
WO2017029602A2 (en) 2017-02-23
AU2019200226B2 (en) 2020-01-23
AU2016307969C1 (en) 2019-09-05
MA42621A (fr) 2018-06-20
US20190031680A1 (en) 2019-01-31
AU2016307969B2 (en) 2019-02-14
IL257265A (en) 2018-03-29
UY36851A (es) 2017-03-31
PE20181143A1 (es) 2018-07-17
CL2018000403A1 (es) 2018-07-06
CN108137616A (zh) 2018-06-08
US10364254B2 (en) 2019-07-30
EP3334739A2 (en) 2018-06-20
JP6757402B2 (ja) 2020-09-16
HK1248680A1 (zh) 2018-10-19
AU2019200226A1 (en) 2019-01-31
JP2018523675A (ja) 2018-08-23
CA2995715A1 (en) 2017-02-23
ZA201800722B (en) 2019-07-31
AU2016307969A1 (en) 2018-03-08
WO2017029602A3 (en) 2017-04-13
PH12018500358A1 (en) 2018-09-03
TW201722965A (zh) 2017-07-01
CR20180111A (es) 2018-04-12
EA201890412A1 (ru) 2018-08-31
KR20180038046A (ko) 2018-04-13
IL257265B (en) 2020-07-30

Similar Documents

Publication Publication Date Title
PH12018500034A1 (en) Bicyclic lactams and methods of use thereof
IL272262A (en) Analogues of 2,1-dihydro-H3-pyrazolo[4,3-D]pyrimidine-3-one
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
GEP20207075B (en) New aminoacid derivatives, a process for their preparation and pharmaceutical compositions containing them
MX2016016593A (es) Nuevos derivados de aminoalquibenzotiazepina y usos de los mismos.
WO2016011222A3 (en) Circular polynucleotides
EA033314B1 (ru) АНТИБАКТЕРИАЛЬНЫЕ АГЕНТЫ, СОДЕРЖАЩИЕ ПИРАЗИНО[2,3-b][1,4]ОКСАЗИН-3-ОН ИЛИ РОДСТВЕННУЮ КОЛЬЦЕВУЮ СИСТЕМУ
MX2017003517A (es) Estimuladores de guanilato ciclasa soluble (sgc).
PH12020500105A1 (en) Bicyclic ketone compounds and methods of use thereof
TW201613864A (en) Novel compounds
EP3102036A4 (en) 3-substituted carbonyl-naphtho[2,3-b]furane derivative or pharmaceutically acceptable salt thereof
MX2017016802A (es) Formulaciones farmaceuticas.
WO2016125192A3 (en) Processes for the preparation of dolute-gravir
IN2013MU01985A (enExample)
MX369451B (es) Formas cristalinas de compuestos basados en 1, 8- naftiridin-4(h)-ona particulares y su uso en el tratamiento de ansiedad y condiciones relacionadas.
PH12018500980A1 (en) Amorphous solifenacin-containing solid preparation for oral use and preparation method therefor
CL2016001024A1 (es) Compuestos derivados de pirido[4,3-b]pirazin-2-carboxamidas; procedimiento de preparacion; composicion farmaceutica y uso para el tratamiento de trastornos neurodegenerativos, esquizofrenia, depresion, entre otras enfermedades.
MA39877A (fr) Formes solides d'un composé pharmaceutiquement actif
WO2016063289A3 (en) Pharmaceutical tablet compositions comprising rifaximin
WO2016020408A3 (en) Compounds for preventing ototoxicity
HK40027677A (en) 1, 2-dihydro-3h-pyrazolo [3, 4-d]pyrimidin-3-one analogs
TR201721065A2 (tr) Deksmedetomi̇di̇n i̇çeren li̇yofi̇li̇ze farmasöti̇k formülasyonlar
CA3006413C (en) Benzo[b][1,6]naphthyridine derivatives as VPPC-tubulin inhibitors
MY182697A (en) Bicyclic lactams and methods of use thereof

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AZ BY KZ KG TJ RU